Show simple item record

dc.contributor.authorMei, Zi
dc.contributor.authorZhang, Kai
dc.contributor.authorLam, Alfred King-Yin
dc.contributor.authorHuang, Junwen
dc.contributor.authorQiu, Feng
dc.contributor.authorQiao, Bin
dc.contributor.authorZhang, Yi
dc.date.accessioned2019-12-20T02:14:02Z
dc.date.available2019-12-20T02:14:02Z
dc.date.issued2019
dc.identifier.issn2045-7634en_US
dc.identifier.doi10.1002/cam4.2733en_US
dc.identifier.urihttp://hdl.handle.net/10072/389904
dc.description.abstractThe modification of chimeric antigen receptor (CAR) endowing T cells with tumor‐specific cytotoxicity induces antitumor immunity. However, the structural characteristics of solid tumors, the loss of specific antigens, and the strong immunosuppressive environment are challenges to treat solid tumors with CAR‐T therapy. The purpose of our study was to find and verify the potentials of CAR‐T therapies for patients with head and neck squamous cell carcinoma (HNSCC). First, we selected MUC1 as our research target and verified its differential expression in cancer tissues and adjacent non‐neoplastic tissues (ANNT). Next, we constructed a second‐generation CAR and validated the cytotoxic function in vitro. In our study, we found that exogenous addition human IL22 recombinant protein could increase the MUC1 expression and enhance the function of T cells. In addition, we constructed a fourth‐generation CAR that secretes IL22. Finally, we verified the antitumor function of two different CAR‐T cells in vitro and in vivo, respectively. CAR‐MUC1‐IL22 T cells were found to have a stronger and more effective cytotoxic function against MUC1 + HNSCC cells. Taken together, these results demonstrate the potential effectiveness of CAR‐T in the treatment of patients with HNSCC and provide evidence‐based of MUC1 + CAR‐T therapy.en_US
dc.description.peerreviewedYesen_US
dc.languageEnglishen_US
dc.publisherWileyen_US
dc.publisher.placeUnited Kingdom
dc.relation.ispartofjournalCancer Medicineen_US
dc.subject.fieldofresearchBiochemistry and Cell Biologyen_US
dc.subject.fieldofresearchOncology and Carcinogenesisen_US
dc.subject.fieldofresearchcode0601en_US
dc.subject.fieldofresearchcode1112en_US
dc.subject.keywordsINFLAMMATIONen_US
dc.subject.keywordsCARCINOMAen_US
dc.subject.keywordsCANCERen_US
dc.subject.keywordsIL-7en_US
dc.subject.keywordsINTERLEUKIN-22en_US
dc.titleMUC1 as a target for CAR-T therapy in head and neck squamous cell carinomaen_US
dc.typeJournal articleen_US
dc.type.descriptionC1 - Articlesen_US
dcterms.bibliographicCitationMei, Z; Zhang, K; Lam, AK-Y; Huang, J; Qiu, F; Qiao, B; Zhang, Y, MUC1 as a target for CAR-T therapy in head and neck squamous cell carinoma, Cancer Medicine, 2019en_US
dcterms.dateAccepted2019-11-10
dcterms.licensehttp://creativecommons.org/licenses/by/4.0/en_US
dc.date.updated2019-12-20T01:07:24Z
dc.description.versionPublisheden_US
gro.description.notepublicThis publication has been entered into Griffith Research Online as an Advanced Online Version.en_US
gro.rights.copyright© 2019 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.en_US
gro.hasfulltextFull Text
gro.griffith.authorLam, Alfred K.


Files in this item

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record